Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Positive Early Breast Cancer”

325 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 325 results

Testing effectiveness (Phase 2)Looking for participantsNCT06927180
What this trial is testing

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital 180
Not applicableUnknownNCT05656079
What this trial is testing

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

Who this might be right for
Breast Cancer
Shanghai Pudong Hospital 204
Testing effectiveness (Phase 2)Active Not RecruitingNCT05710666
What this trial is testing

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

Who this might be right for
HER2-positive Breast Cancer
Cancer Trials Ireland 11
Large-scale testing (Phase 3)Ended earlyNCT06038539
What this trial is testing

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Who this might be right for
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd 55
Not applicableEnded earlyNCT02771795
What this trial is testing

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Who this might be right for
Breast Neoplasms
Samsung Bioepis Co., Ltd. 538
Not applicableApproved For MarketingNCT04100694
What this trial is testing

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Who this might be right for
NRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more
Merus B.V.
Testing effectiveness (Phase 2)Study completedNCT01973660
What this trial is testing

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 151
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07287098
What this trial is testing

Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 600
Large-scale testing (Phase 3)UnknownNCT05985187
What this trial is testing

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Who this might be right for
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 412
Testing effectiveness (Phase 2)UnknownNCT04659499
What this trial is testing

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

Who this might be right for
Early Breast Cancer
Peking Union Medical College Hospital 261
Not applicableLooking for participantsNCT06930521
What this trial is testing

JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year

Who this might be right for
Cardiovascular HealthBreast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)+4 more
Women's College Hospital 300
Testing effectiveness (Phase 2)Looking for participantsNCT05035836
What this trial is testing

Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Who this might be right for
Breast CancerHER2-positive
M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)Study completedNCT01565200
What this trial is testing

HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1

Who this might be right for
HER-2 Positive Breast Cancer
Jules Bordet Institute 90
Testing effectiveness (Phase 2)Looking for participantsNCT07102381
What this trial is testing

Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerBreast Cancer
Jazz Pharmaceuticals 125
Not applicableLooking for participantsNCT06534125
What this trial is testing

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more
Emory University 150
Large-scale testing (Phase 3)Study completedNCT03588091
What this trial is testing

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 355
Large-scale testing (Phase 3)Study completedNCT02162667
What this trial is testing

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

Who this might be right for
HER2-positive Carcinoma of Breast
Celltrion 562
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Large-scale testing (Phase 3)Active Not RecruitingNCT03595592
What this trial is testing

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

Who this might be right for
Invasive Breast Cancer
Fondazione Michelangelo 650
Large-scale testing (Phase 3)Study completedNCT03989037
What this trial is testing

SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Shanghai Institute Of Biological Products 580
Load More Results